NCT04452929View on ClinicalTrials.gov

The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

NAUnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

July 31, 2022

Conditions
MigraineMigraine Without AuraMigraine With Aura
Interventions
DRUG

Erenumab

Subcutaneous injection of 140 mg erenumab.

DRUG

Placebo

Subcutaneous injection of saline placebo.

DRUG

Calcitonin gene-related peptide

Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.

DRUG

Cilostazol

Oral intake of 200 mg cilostazol.

Trial Locations (1)

2600

RECRUITING

Danish Headache Center, Glostrup Municipality

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Danish Headache Center

OTHER